COMING UP | WEBINAR 6
INSULIN RESISTANCE IN NAFLD
November 29, 2022 - 17.00 - 18.00 CET
|
Speaker: Dr. Onno Holleboom
Topic: This webinar will focus on the close multilevel links between insulin resistance/T2DM and NAFLD:
Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Dr. Onno Holleboom 
|
WEBINAR 5 | Genetic architecture of NAFLD: where do we stand?
september 27, 2022 - 17.00 - 18.00 CEST
|
Topic: Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelling new insights into the biology of NAFLD and highlighted potentially attractive pharmaceutical targets. Professor Eric Trépo also discussed potential applications and limitations of genetic variations for risk prediction in this disease.
Speaker: Prof. Eric Trépo Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Eric Trépo 
|
WEBINAR 4 | PUBLIC HEALTH AND POLICY RESPONSES TO NAFLD/NASH
JUNE 14, 2022 - 17.00 - 18.00 CESTTopic: This webinar by professor Lazarus focused on the impact of NAFLD and NASH and what is currently being done to tackle this disease nationally and globally. During his talk, the speaker identified what still needs to be done in the fight against NAFLD/NASH and how countries can advance the battle against this “silent” condition.
Speaker: Prof. Dr. Jeffrey Lazarus Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Jeffrey Lazarus 
|
WEBINAR 3 | Non-invasive diagnosis and disease staging of nafld
MARCH 22, 2022 - 17.00 - 18.00 CET
|
Guest Speaker
Prof. Hannes Hagström 
|
WEBINAR 2 | Promising phase 2 trial results of Lanifibranor in NASH
February 1, 2022 - 17.00 - 18.00 CET
|
Topic:
In this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment. Speaker: Prof. Sven Francque Host: Dr. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Sven Francque 
|
|
|
WEBINAR 1 | NAFLD: Patient Identification strategies
NOVEMBER 9, 2021 - 17.00 - 18.00 CET
|
Topic:
In this webinar Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely implemented and therefore this represents an unmet clinical need. Professor Schattenberg’s paper includes recommendations to address the increasing need for comprehensive models of care for NAFLD. Speaker: Prof. Jörn Schattenberg Host: Dr. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Jörn Schattenberg 
|
NASH Webinar Series |
These webinars are part of the NASH webinar series, each focusing on recent developments or publications on nonalcoholic steatohepatitis (NASH). The topics and publications are selected by KOLs of NASH Clinical based on relevant ground-breaking NASH research in a high-impact journal. During these webinars we offer you the opportunity to interact with original authors and experts in the NASH field.
|
|
HOST
CO-HOST
|
